Jorge A. U.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer
- Phase 3 Randomized Study of Perioperative Dostarlimab vs. Standard of Care in Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- Evaluation of Pembrolizumab and Olaparib in Homologous-Recombination Deficient Metastatic Colorectal Cancer: A Phase II Clinical Trial
Data & Insights
Has run more than one trial at 69 of 209 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced colorectal cancer and anal canal carcinoma, with particular focus on innovative therapeutic approaches for patients with specific genetic markers.
- Colorectal cancer treatment strategies
- Squamous cell carcinoma of the anal canal
- dMMR/MSI-H colon cancer management
Expertise includes perioperative treatment approaches and combination therapy protocols for gastrointestinal malignancies.
Targeted Oncology
The investigator focuses on treating tumors with specific genetic mutations, particularly those with KRAS-G12D mutations. Their work encompasses novel therapeutic approaches in pancreatic ductal adenocarcinoma.
- KRAS-mutated tumor therapies
- Pancreatic cancer treatment
- Molecular targeted therapies
Specializes in developing treatment strategies for genetically characterized tumors.
Thoracic Oncology
The investigator has expertise in treating non-small cell lung cancer, with emphasis on innovative combination therapies and immunotherapy approaches.
- Advanced lung cancer treatments
- Immunotherapy combinations
- Chemoradiotherapy protocols
Focus includes developing treatment protocols that combine multiple therapeutic modalities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.